Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04620681 · ClinicalTrials.gov registry record · Phase 1
CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML
A Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT04620681 is a Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 19 participants.
The verdict
NCT04620681, a Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the safety of an investigational treatment for myelodysplastic syndrome (MDS) after the first therapy (such as azacitidine or decitabine) stops working or after progression of MDS to acute myeloid leukemia (AML). Funding source - FDA OOPD.
Interventions
- DRUG Standard of Care Chemotherapy
- BIOLOGICAL CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2021-01-14 |
| Est. Completion | 2024-07-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04620681
The ClinicalTrials.gov registry entry for NCT04620681 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care Chemotherapy is the first listed.
NCT04620681 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04620681 about?
NCT04620681 is a clinical study titled "CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML". The purpose of the study is to determine the safety of an investigational treatment for myelodysplastic syndrome (MDS) after the first therapy (such as azacitidine or decitabine) stops working or after progression of MDS to acute myeloid leukemia (AML). Funding source - FDA OOPD.
What is the current status of trial NCT04620681?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2021-01-14. Estimated completion is 2024-07-20.
What interventions are being tested in trial NCT04620681?
The interventions under investigation include: Standard of Care Chemotherapy (DRUG), CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT04620681?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.